Glioblastoma: open trials in China

57 open trials have a site in China. Registry data; only the trial team decides who can take part.

NCT07180927
DLL3 CAR-T Therapy Targeting Brain Tumors
Trial Treatment · Phase 1/2 · Shenzhen Geno-Immune Medical Institute
Shenzhen Geno-immuno Medical Institute, Shenzhen
Registry updated 2026-11-02
NCT03914768
Immune Modulatory DC Vaccine Against Brain Tumor
Trial Treatment · Phase 1 · Shenzhen Geno-Immune Medical Institute
Shenzhen Geno-immune Medical Institute, Shenzhen
Registry updated 2026-10-30
NCT07093814
A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma
Trial Treatment · Phase 1/2 · Guangzhou Virotech Pharmaceutical Co., Ltd.
Sanbo Brain Hospital, Capital Medical University, Beijing · The Cancer Hospital Affiliated to Chongqing University, Chongqing · Nanfang Hospital, Southern Medical University, Guangzhou · Sun Yat-sen University Cancer Center, Guangzhou · The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou · The First Affiliated Hospital of USTC, Hefei · Qilu Hospital of Shandong University, Jinan · Guangxi Medical University Cancer Hospital, Nanning · Shenzhen Second People's Hospital, Shenzhen · Tangdu Hospital of Air Force Medical University of the PLA, Xi’an · The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai
Registry updated 2026-10-29
NCT06914128
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
Trial Treatment · Phase 1/2 · Bayer
Beijing chest hospital, Capital Medical University, Beijing · Beijing Cancer Hospital - Oncology Department, Beijing · Sir Run Run Shaw Hospital, Zhejiang Univ. School of Medicine - Oncology Department, Hangzhou · Jiangsu Provincial People's Hospital - The First Affiliated Hospital of Nanjing Medical University, Nanjing · Tongji Hosp. of Tongji Med Coll, Huazhong Uni of Sci & Tech., Wuhan
Registry updated 2026-10-28
NCT07297212
A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma
Trial Treatment · Phase 2 · BioNTech SE
Beijing Tiantan Hospital,Capital Medical University, Beijing · Affiliated Tumor Hospital of Chongqing Medical University, Chongqing · Affiliated Cancer Hospital of Shandong First Medical University, Jinan · Huashan Hospital, Fudan University, Shanghai · Shenzhen Second People's Hospital, Shenzhen · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Registry updated 2026-10-28
NCT05303519
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
Trial Treatment · Phase 3 · Nuvation Bio Inc.
Peking Union Medical College Hospital, Beijing · Xuanwu Hospital, Capital Medical University, Beijing · Sanbo Brain Hospital, Capital Medical University, Beijing · Beijing Tiantan Hospital,Capital Medical University, Beijing · Xiangya Hospital of Central South University, Changsha · West China Hospital of Sichuan University, Chengdu · The First Affiliated Hospital of Fujian Medical University, Fuzhou · Sun Yat-sen University Cancer Center, Guangzhou · Huashan Hospital Affiliated to Fudan University, Shanghai
Registry updated 2026-10-19
NCT07873996
Tris-CAR-T Cell Therapy Targeting CD44 and CD133 in Newly Diagnosed Glioblastoma
Trial Treatment · Phase 2/3 · Beijing Tiantan Hospital
Beijing Tiantan Hospital,Capital Medical University, Beijing
Registry updated 2026-10-14
NCT07831187
Entacapone Plus Bevacizumab for Glioblastoma at First Recurrence
Trial Treatment · Phase 1/2 · First Affiliated Hospital of Wenzhou Medical University
The First Affiliated Hospital of Wenzhou Medical University, Wenzhou
Registry updated 2026-09-21
NCT07758062
Levetiracetam Extended-Release Plus Stupp Protocol for Hypoxic IDH-Wildtype Glioblastoma
Trial Treatment · Phase 2 · Tianjin Medical University General Hospital
Tianjin Medical University General Hospital, Tianjin
Registry updated 2026-08-11
NCT07501559
A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM)
Trial Treatment · Phase 1/2 · Jecho Biopharmaceuticals Co., Ltd.
Huashan Hospital, Shanghai Medical College, Fudan University & Beijing TianTan Hospital,Capital Medical University, Shanghai
Registry updated 2026-08-10
NCT07244835
A Study of DEG6498 in Participants With Solid Tumors
Trial Treatment · Phase 1 · Degron Therapeutics Co.
Beijing Cancer Hospital, Beijing · Beijing GoBroad Hospital, Beijing · Sun Yat-sen University Cancer Center, Guangzhou
Registry updated 2026-06-30
NCT07670026
Intensified Adjuvant Therapy for High-Risk Newly Diagnosed Glioblastoma With Subtotal Resection or Short-Term Progression
Trial Treatment · Phase 2 · Second Affiliated Hospital, Zhejiang University, School of Medicine
The Second Affiliated Hospital,School of Medicine,Zhejiang University, Hangzhou
Registry updated 2026-06-25
NCT07655869
[177Lu]Lu-DOTA-EB-RGD2 Therapy in Patients With Recurrent High-grade Glioma
Trial Treatment · Early phase 1 · Beijing Tiantan Hospital
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing · Beijing Tiantan Hospital,Capital Medical University, Beijing
Registry updated 2026-06-18
NCT07648823
Dosimetry, Safety, and Efficacy Study of [177Lu]Lu-XT771 in Patients With Recurrent Glioblastoma
Trial Treatment · Early phase 1 · Beijing Tiantan Hospital
Beijing Tiantan Hospital,Capital Medical University, Beijing · Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing
Registry updated 2026-06-16
NCT07608003
Multicenter Prospective Study on MRI AI Model for Midline Glioma Subtyping and Prognosis:
Research · Xiangya Hospital of Central South University
Xiangya Hospital of Central South University, Changsha
Registry updated 2026-05-27
NCT07552233
NK Cell Therapy for Malignant Solid Brain Tumors
Trial Treatment · Peking University Third Hospital
Peking University Third Hospital, Beijing · Qinhuangdao Runze Hospital, Qinhuangdao · Zhengzhou Second Hospital, Zhengzhou · Henan Academy of Innovations in Medical Science, Zhengzhou
Registry updated 2026-04-27
NCT07552467
Sub-topic Four: Clinical Translation of Original Radioactive Drugs for Precision Diagnosis and Treatment of Gastrointestinal Tumors -Clinical Application Value of PET Imaging Targeting LRRC15 in Malignant Tumors
Research · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan Union Hospital, China, Wuhan
Registry updated 2026-04-27
NCT07551336
Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma
Trial Treatment · Phase 1 · Beijing Biotech
Peking University Shenzhen Hospital, Shenzhen
Registry updated 2026-04-24
NCT07538128
Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent Glioblastoma
Trial Treatment · Early phase 1 · Huashan Hospital
Huashan Hospital, Shanghai
Registry updated 2026-04-20
NCT07523529
Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
Trial Treatment · Phase 1/2 · Beijing Biotech
Peking University Shenzhen Hospital, Shenzhen
Registry updated 2026-04-13
NCT07520214
Clinical Study on the Safety and Immunogenicity of Specific Cancer Vaccines in Preventing Recurrence of Glioblastoma
Trial Treatment · Early phase 1 · Beijing Neurosurgical Institute
Beijing Tiantan Hospital, Beijing
Registry updated 2026-04-09
NCT07511725
Prophylactic Regimen With Intrathecal Thiotepa in SVZ-positive or Meningeal-risk Glioblastoma
Trial Treatment · Phase 2 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2nd Affiliated Hospital, School of Medicine, Hangzhou
Registry updated 2026-04-06
NCT07480941
Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma
Trial Treatment · Phase 1 · Beijing Biotech
Peking University Shenzhen Hospital, Shenzhen
Registry updated 2026-03-18
NCT07455045
A Phase I Study of FZ-AD005 in Patients With High-Grade Glioma (HGG)
Trial Treatment · Phase 1 · Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Sun Yat-sen University Cancer Center, Guangzhou
Registry updated 2026-03-06
NCT07318818
A Clinical Trial of P134 Cells in Recurrent Glioblastoma
Trial Treatment · Phase 1/2 · Tasly Pharmaceutical Group Co., Ltd
Beijing Tiantan Hospital,Capital Medical University, Beijing
Registry updated 2026-02-18

All Glioblastoma trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error